News Conference News HFSA 2025 Too Few HF Patients on Guideline-Directed Medical Therapy in VA System Yael L. Maxwell October 06, 2025
News Conference News HFSA 2025 Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM Yael L. Maxwell October 01, 2025
News Conference News HFSA 2025 CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF Yael L. Maxwell September 29, 2025
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER Caitlin E. Cox October 03, 2024
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News HFSA 2020 Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study L.A. McKeown October 12, 2020
News Conference News HFSA 2019 Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention L.A. McKeown September 24, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019